

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (JK-98) IERAMILIMAB

PRONUNCIATION eye" er a mil' i mab

THERAPEUTIC CLAIM Antineoplastic

CHEMICAL NAMES

1. Immunoglobulin G4, anti-(human lymphocyte activation gene-3 protein) (human-*Mus musculus* monoclonal clone NVS250617 γ 4-chain), disulfide with human-*Mus musculus* monoclonal clone NVS250617 κ -chain, dimer (Source: CAS)
2. immunoglobulin G4-kappa, anti-[*Homo sapiens* LAG3 (lymphocyte activating 3, lymphocyte-activation 3, CD223)], humanized monoclonal antibody; gamma4 heavy chain humanized (1-451) [VH (*Homo sapiens* IGHV7-4-1*02 (85.7%) -(IGHD) -IGHJ4*01 (92.3%)) [8.8.18] (1-125) -*Homo sapiens* IGHG4*01 (CH1 (126-223), hinge S10>P (233) (224-235), CH2 (236-345), CH3 (346-450), CHS K2>del (451)) (126-451)], (139-214')-disulfide with kappa light chain humanized (1'-214') [V-KAPPA (*Homo sapiens* IGVK1-33*01 (83.2%) -IGKJ1*01 (100%)) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (231-231":234-234")-bisdisulfide (Source: WHO pINN list 120)

STRUCTURAL FORMULA

Heavy chain X & X''

QVQLVQSGAE	VKKPGASVKV	SCKASGFTLT	NYGMNWRQA	RGQRLEWIGW	50
INTDTGEPY	ADDFKGRFVF	SLDTSVSTAY	LQISSLKAED	TAVYYCARNP	100
PPYYGTNNAE	AMDYWGQGT	VTVSSASTKG	PSVFPPLPCS	RSTSESTAAL	150
GCLVKDYFPE	PVTVSWNSGA	LTSGVHTFPA	VLQSSGLYSL	SSVVTVPSSS	200
LGTKTYTCNV	DHKPSNTKVD	KRVESKYGPP	CPPCPAPEFL	GGPSVFLFPP	250
KPKDTLMISR	TPEVTCVVVD	VSQEDPEVQF	NWYVDGVEVH	NAKTKPREEQ	300
FNSTYRVVSV	LTVLHQDWLN	GKEYKCKVSN	KGLPSSIEKT	ISKAKGQPRE	350
PQVYTLPPSQ	EEMTKNQVSL	TCLVKGFYPS	DIAVEWESNG	QPENNYKTTP	400
PVLDSDGSFF	LYSRLTVDKS	RWQEGNVFSC	SVMHEALHNN	YTQKSLSLSL	450
G					501

Light chain X' & X'''

DIQMTQSPSS	LSASVGRVVT	ITCSSSQDIS	NYLNWYLQKP	GQSPQLLIYY	50'
TSTLHLGVPS	RFSGSGSGTE	FTLTISSLQP	DDFATYYCQQ	YYNLPWTFGQ	100'
GTKVEIKRTV	AAPSVFIFPP	SDEQLKSGTA	SVVCLLNNFY	PREAKVQWKV	150'
DNALQSGNSQ	ESVTEQDSKD	STYLSSTLT	LSKADYEKHK	VYACEVTHQG	200'
LSSPVTKSFN	RGEC				214'

Disulfide bridges location

22-96	22"-96"	23'-88'	23'''-88'''	134'-194'	134'''-194'''	139-214'	139"-214'''
152-208	152"-208"	231-231"	234-234"	266-326	266'''-326'''	372-430	372"-430"

Modified residues



Glycosylation sites (N)

Asn-302 Asn-302''

MOLECULAR FORMULA	C ₆₅₁₄ H ₉₉₇₄ N ₁₇₀₆ O ₂₀₅₆ S ₄₄
MOLECULAR WEIGHT	146.5 kDa
TRADEMARK	None as yet
SPONSOR	Novartis
CODE DESIGNATIONS	LAG-525, NVP-LAG525
<u>CAS</u> REGISTRY NUMBER	2137049-37-5
UNII	OI8P0SFD4R
WHO NUMBER	11005

gbk